Dysregulation of miR-125b predicts poor response to therapy in pediatric acute lymphoblastic leukemia
Loading...
Date
2019
Journal Title
Journal ISSN
Volume Title
Type
Article
Publisher
Wiley-Liss Inc.
Series Info
Journal of Cellular Biochemistry
120
120
Scientific Journal Rankings
Abstract
Background: Acute lymphoblastic leukemia (ALL) is the most well-known sort of leukemia in children. In spite of favorable survival rates, some patients relapse and achieve a poor outcome. Methods: We analyzed miR-125b and Bcl-2 expressions in pediatric patients with ALL and evaluated their clinical utility as molecular markers for the prediction of disease outcomes. Results: Downregulation of miR-125b and increased Bcl-2 expression levels in pediatric patients with ALL were associated with poor prognosis at diagnosis. At day 28 of induction, miR-125b was significantly increased, whereas Bcl-2 was downregulated. Loss of miR-125b during diagnosis and its elevation after therapy are strongly correlated with short leukemia-free survival and worse survival. Moreover, the combination of miR-125b with Bcl-2 markers can clearly enhance the prediction of the disease outcome. Finally, a univariate analysis highlighted the independent prognostic value of miR-125 in a pediatric patient with ALL. Conclusions: miR-125b and Bcl-2 together are potent predictors for the prognosis and, therefore, can be used as therapeutic targets in childhood ALL. � 2018 Wiley Periodicals, Inc.
Description
Scopus
MSA Google Scholar
MSA Google Scholar
Keywords
October University for Modern Sciences and Arts, جامعة أكتوبر للعلوم الحديثة والآداب, University of Modern Sciences and Arts, MSA University, Bcl-2, childhood acute lymphoblastic leukemia (ALL), miR-125b, prognostic factors, antileukemic agent, microRNA 125b, protein bcl 2, acute lymphoblastic leukemia, Article, cancer chemotherapy, cancer prognosis, cancer specific survival, child, childhood leukemia, clinical outcome, controlled study, down regulation, female, gene expression, human, major clinical study, male, predictive value, priority journal, treatment response